Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Filamon LTD
Neonc Technologies, Inc.
Essen Biotech
Essen Biotech
Sapience Therapeutics
xCures
Mayo Clinic
Degron Therapeutics Co.
GlaxoSmithKline
Massive Bio, Inc.
University of Arizona
Incyte Corporation
Stanford University
Cedars-Sinai Medical Center
Sheffield Teaching Hospitals NHS Foundation Trust
BerGenBio ASA
Taproot Health
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
ABM Therapeutics Corporation
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
Sumitomo Pharma America, Inc.
Karyopharm Therapeutics Inc
Quadriga Biosciences, Inc.
M.D. Anderson Cancer Center
Genexine, Inc.
Hospices Civils de Lyon
SpeciCare
AbbVie
DEKK-TEC, Inc.
Case Comprehensive Cancer Center
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Celgene
Massachusetts General Hospital
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
Icahn School of Medicine at Mount Sinai
Swiss Cancer Institute
Stanford University
Center Trials & Treatment
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)